What are OX40 agonist monoclonal antibody drugs?

OX40 agonist monoclonal antibody drugs are pharmacologic agents that share a common mechanism (typically targeting OX40 (TNFRSF4)). 0 are currently marketed, with 6 more in clinical development.

OX40 agonist monoclonal antibody

0 marketed 6 in Phase 3

This page covers all OX40 agonist monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting OX40 (TNFRSF4), OX40 (CD134), OX40.

Targets

OX40 (TNFRSF4) · OX40 (CD134) · OX40

Phase 3 pipeline (6)

GSK1325760A · GlaxoSmithKline · Oncology
GSK1325760A is a monoclonal antibody that blocks OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
CM326 · Keymed Biosciences Co.Ltd · Oncology
CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
PF-05280586 · Pfizer · Oncology
PF-05280586 is a monoclonal antibody that blocks OX40, a costimulatory receptor on T cells, to enhance anti-tumor immune responses.
KW-2246 · Kyowa Kirin Co., Ltd. · Oncology
KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
KN057 · Suzhou Alphamab Co., Ltd. · Oncology
KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.
MK-3415A · Merck Sharp & Dohme LLC · Oncology
MK-3415A is a monoclonal antibody that targets and inhibits OX40, a costimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.